Here’s what you should know:
1. Dr. Alistar has been at the forefront of CPI-613 research. She conducted early stage clinical trials of the treatment and will serve as co-principal investigator on a phase-III combination therapy study of CPI-613 and modified Folfirinox.
2. In addition to this upcoming study, Dr. Alistar led four other clinical trials for CPI-613, as well as several for oncology drugs.
3. She said, “Pancreatic cancer has a very low survival rate. This is due in part to the fact that it is often discovered in a late stage. Early detection can make a difference.”
More articles on gastroenterology:
Tufts Medical Center, Texas Gastroenterology Institute & more: 6 GI practices in the news
FDA approves Synergy Pharmaceuticals’ Trulance for adults with IBS-C — 3 insights
AGA launches patient app aimed at IBD monitoring, education — 3 insights
